MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management
- DOI
- 10.1053/j.seminhematol.2026.01.002
- Published
- 2025-10
- Container
- Seminars in Hematology
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1053/j.seminhematol.2026.01.002,
title = {MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management},
author = {Ola Landgren and Rafat Abonour and Dickran Kazandjian},
year = {2025},
journal = {Seminars in Hematology},
doi = {10.1053/j.seminhematol.2026.01.002},
url = {https://doi.org/10.1053/j.seminhematol.2026.01.002}
}RIS
TY - JOUR TI - MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management AU - Ola Landgren AU - Rafat Abonour AU - Dickran Kazandjian PY - 2025 JO - Seminars in Hematology DO - 10.1053/j.seminhematol.2026.01.002 UR - https://doi.org/10.1053/j.seminhematol.2026.01.002 ER -
APA
Landgren, O., Abonour, R., & Kazandjian, D. (2025). MRD in multiple myeloma: From an early endpoint for accelerated approval to MRD driven treatment and clinical management. Seminars in Hematology. https://doi.org/10.1053/j.seminhematol.2026.01.002
Source records
- crossref · retrieved 2026-09-26T01:30:53.426Z